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Abstract 1 
Aims/Introduction: The predictive low glucose management (PLGM) system was introduced in 2 
March 2018 in Japan. Although there are some reports demonstrating the benefit of PLGM in 3 
preventing hypoglycemia, no data are currently available in Japanese patients with type 1 diabetes 4 
mellitus (T1DM). The aim of the present study is to evaluate the effect of PLGM with sensor-5 
augmented pump therapy in the prevention of hypoglycemia in Japanese patients. 6 
7 
Materials and Methods: We included 16 patients with T1DM who used the MiniMed®640G system 8 
after switching from the MiniMed®620G system. We retrospectively analysed the data of the 9 
continuous glucose monitoring system in one month after switching to MiniMed®640G. 10 
11 
Results: The area under the curve (AUC) of hypoglycemia of <70 mg/dL was lowered from 0.42 ± 12 
0.43 mg/dL· day to 0.18 ± 0.18 mg/dL· day (P=0.012). Correspondingly, the duration of severe 13 
hypoglycemia (<54 mg/dL) was reduced significantly from 15.3 ± 21.7 min/day to 4.8 ± 6.9 min/day 14 
(P=0.019). The duration of hypoglycemia were reduced, but the reduction was not significant. 15 
Regarding the AUC for hyperglycemia >180 mg/dL and the duration of hyperglycemia did not change. 16 
With the PLGM function, 79.3% of the predicted hypoglycemic events were avoided. 17 
18 
Conclusions: The hypoglycemic reduction rate was comparable to those in previous reports. In 19 
addition, we demonstrated that PLGM can markedly suppress severe hypoglycemia without 20 
deteriorating glycemic control in Japanese T1DM patients. It is necessary to further investigate the 21 
more effective use of the PLGM feature such as establishing a lower limit and the timing of resumption. 22 
23 
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Introduction 1 
Currently, insulin pump therapy is one of the important treatment methods for type 1 diabetes 2 
mellitus (T1DM). Since sensor-augmented pumps (SAP) equipped with real-time continuous glucose 3 
monitoring (CGM) were launched in recent years, the management of glycemic control for individuals 4 
with T1DM has greatly advanced. Although these new medical devices such as CGM and SAP have 5 
enabled the prevention of severe hypoglycemia [1-6], the preventive effects have still not been 6 
satisfactory, especially in cases aiming for strict glycemic control. For these circumstances, the 7 
MiniMed®640G system (Medtronic, Northridge, CA, USA) was made commercially available in 8 
Japan in March 2018. This system includes a predictive low glucose management (PLGM) algorithm, 9 
in which insulin delivery is suspended when the sensor glucose (SG) value is predicted to be 20 mg/dl 10 
above the pre-set limit in 30 min. Previous studies have shown preventive effects on hypoglycemia in 11 
which 75 to 83% of cases of predicted hypoglycemia can be avoided without deteriorating glycemic 12 
control by using the PLGM feature [7, 8], but the clinical utility of the device in Japan has remained 13 
unknown. 14 
In this study, we investigated the hypoglycemia-preventive effect of switching from the 15 
MiniMed®620G (Medtronic, Northridge, CA, USA) system to the MiniMed®640G system in Japanese 16 
patients with T1DM. We analysed glycemic profiles with the use of CGM data before and after 17 
changing the equipment. 18 
19 
Materials and Methods 20 
This study was a retrospective observational study that was approved by the ethics committee of 21 
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 22 
(approval no. ken1812-016, approval date. 14 December 2018). We switched from the 23 
MiniMed®620G system to the MiniMed®640G system between April 2018 and October 2018 for all 24 
21 patients with T1DM who are on SAP therapy at Okayama University Hospital. We included only 25 
16 of these patients (4 males and 12 females) because the inclusion criteria for this study was 26 
4 
4 
patients who used CGM for 5 days/week or more. Baseline characteristics of the participants were 1 
shown in Table 1. 2 
We retrospectively investigated the glycemic profile, insulin administration status and CGM data 3 
before and 1 month after changing to the MiniMed®640G system using the CGM analysis software 4 
(CareLink® Pro Therapy Management Software, Medtronic). Insulin administration status included 5 
total daily insulin dose (TDD), total basal insulin dose (TBD), and the percentage of total basal 6 
insulin dose to total daily insulin dose (%TBD); HbA1c and glycated albumin (GA) were used as the 7 
glycemic profile. We analysed the mean SG value, the number of insulin suspensions by PLGM 8 
(PLGM event), the duration of insulin suspension, severe hypoglycemia (< 54 mg/dL), 9 
hypoglycemia (< 70 mg/dL)  and hyperglycemia (> 180 mg/dL), the areas under the curve (AUCs) 10 
for hypoglycemia and hyperglycemia and the carbohydrate values that the patients input for 11 
automatic bolus calculation as the CGM data. In addition, we investigated the SG value at the time 12 
of suspension initiation, the lowest SG value during suspension, the SG value at the resumption of 13 
insulin infusion and the SG value 1 hour after initiating insulin infusion. All patients did not change 14 
the basal insulin setting or carbohydrate-to-insulin ratio after the initiation of PLGM, and all patients 15 
used the automatic bolus calculation function of the insulin pump. The preset lower limit value when 16 
the PLGM feature was introduced was 70 mg/dL. Because previous report advocated that in case of 17 
suspension, patients should monitor the trend and delay hypoglycemia treatment to ‘‘let the pump do 18 
the work’’ [9], we recommended all patients not to resume insulin infusion manually during 19 
suspension. However, we also advised them to resume insulin infusion manually at meals, even in 20 
suspension mode, because they could not administer bolus insulin infusion while suspended. In 21 
addition, we instructed patients not to perform preventive supplementation as much as possible 22 
during suspension. 23 
24 
Statistical Analysis 25 
5 
5 
All data are presented as the mean ± SD. Differences in HbA1c, GA, TDD, TBD, %TBD, and the 1 
carbohydrate values measured before and after the change in treatment were analysed with the 2 
Wilcoxon signed-rank test. Other statistical data were assessed with a Mann-Whitney U test. All 3 
statistical analyses were performed with SPSS software version 20 (IBM SPSS statistics). A P value 4 
of < 0.05 was considered statistically significant. 5 
6 
Results 7 
Glycemic control markers and insulin administration status 8 
Both the HbA1c and GA values were unchanged from before to after the PLGM feature was 9 
introduced (HbA1c：7.0 ± 0.8% vs. 7.0 ± 0.9%, P=0.867, GA：19.5 ± 4.2% vs. 20.1 ± 3.5%, P=0.400). 10 
TDD, TBD and %TBD all decreased after the PLGM feature was introduced, but this reduction was 11 
not statistically significant (Table 2). 12 
CGM data 13 
There was no significant change in mean SG value, the duration of hyperglycemia or the AUC of 14 
hyperglycemia >180 mg/dl from before to after the PLGM feature was introduced. No significant 15 
decrease was observed in the duration (58.2 ± 49.4 min/day vs. 30.1 ± 25.9 min/day, P=0.067) of 16 
hypoglycemia. In contrast, the duration of severe hypoglycemia (15.3 ± 21.7 min/day vs. 4.8 ± 6.9 17 
min/day, P=0.019) and the AUC of hypoglycemia <70 mg/dL (0.42 ± 0.43 mg/dL· day vs. 0.18 ± 18 
0.18 mg/dL· day, P=0.012) were both significantly reduced (Table 3). There were no episodes of 19 
diabetic ketoacidosis (DKA) or serious device-related adverse events during the research period. 20 
PLGM operation status and hypoglycemia avoidance rate 21 
There were 1,345 PLGM events during the research period, for a rate of 3.0 ± 1.2 per subject per 22 
day. In addition, the overall mean duration of suspension before hypoglycemic events was 156 ± 46 23 
min/day. Moreover, 1,067 out of the 1,345 events did not reach the preset threshold; that is, 79.3% of 24 
the predicted hypoglycemia was avoided (Fig. 1a). This hypoglycemia avoidance rate was similar in 25 
the daytime (8:00 until 22:00) and night-time (22:00 until 8:00) (Fig. 1b). 26 
6 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
The change in SG value during suspension and after resumption of insulin infusion 
 We further investigated the SG value at the time of suspension initiation (start), the lowest SG value 
during suspension (nadir), the SG value at the resumption (resumption) and the SG value 1 hour after 
resumption (resumption 1 hour). The mean SG value 1 hour after resumption increased to 136.7±16.7 
mg/dL (Fig. 2a), and the mean suspension duration was 55.2 ± 10.6 min. In the comparison of daytime 
and night-time SG values, it was determined that the mean SG value at the start, nadir, resumption and 
resumption 1 hour were all higher in the daytime, but the differences were not significant (start: 102.8 
± 5.2 mg/dL vs. 100.5 ± 4.9 mg/dL, P=0.110, nadir: 84.6 ± 5.1 mg/dl vs 82.9 ± 6.1 mg/dl, P=0.323, 
resumption: 101.7 ± 6.5 mg/dL vs. 97.8 ± 6.2 mg/dL, P=0.094, resumption 1 hour: 140.1 ± 19.1 mg/dL 
vs. 128.5 ± 14.8 mg/dL, P=0.110) (Fig. 2b). In addition, the mean suspension time was significantly 
longer in the night-time than in the daytime (49.1 ± 10.2 min vs. 70.2 ± 16.0 min, P<0.0005). 
 Furthermore, we compared the SG value and the suspension time by 2-quantile groups such as BMI 
(high BMI group with BMI≥22, n=8; low BMI group with BMI<22, n=8), TDD (high TDD group 
with TDD≥38.7, n=8; low TDD group with TDD<38.7, n=8), TBD (high TBD group with TDD≥17.8, 
n=8; low TDD group with TDD<17.8, n=8) and %TBD (high %TBD group with %TBD>30, n=8; 
low %TBD group with %TBD≤30, n=8). We did not find a difference in SG value by BMI (Fig. 2c), 
TDD and TBD at any time point. Similarly, there was no difference in the mean suspension time. In 
contrast, the SG value at resumption 1 hour was significantly higher in the high %TBD group than in 
the low %TBD group (148.8 ± 12.9 mg/dl vs 124.6 ± 9.9 mg/dl, P=0.001) (Fig. 2d) without 
differences of the mean suspension time (57.2 ± 8.4 min vs. 53.2 ± 12.1 min, P=0.645).  
Hyperglycemia after suspension 
There were some cases in which the duration of hyperglycemia was increased by completely 
relying on the algorithm. Fig. 3a shows a case of hyperglycemia after 2 hours’ suspension while 
sleeping. Fig. 3b shows a case of severe hyperglycemia after suspension of insulin infusion because 
PLGM started just after meal. 
Discussion 
6 
27 
7 
7 
Despite advances in medicine and medical devices, hypoglycemia remains a critical issue in the 1 
treatment of T1DM. In recent years, the MiniMed®640G system equipped with a PLGM function 2 
became available, and an improvement in the hypoglycemia avoidance rate is expected. We analysed 3 
hypoglycemia prevention in Japanese T1DM patients using SAP therapy before and after switching 4 
from the MiniMed®620G system to the MiniMed®640G system. In this study, there was a declining 5 
trend in the duration of hypoglycemia, and the duration of severe hypoglycemia and the AUC of <70 6 
mg/dL were both significantly reduced. The hypoglycemia avoidance rate was 79.3%, which was 7 
almost the same in both the daytime and night-time. Moreover, the duration of hyperglycemia, the 8 
AUC of >180 mg/dL, and the values of HbA1c and GA did not increase. From these results, it was 9 
shown that the risk of hypoglycemia is lowered by using the PLGM feature without deteriorating 10 
glycemic control, at least in the short-term. 11 
Similar results have been reported in Western countries. Zhong A and colleagues retrospectively 12 
examined the effect of PLGM, and they reported that both hypoglycemic (SG <70 mg/dL) and 13 
hyperglycemic (SG >240 mg/dL) exposure time decreased in patients using PLGM [8]. Biester T et 14 
al. reported that the frequency and duration of hypoglycemia and the AUC <70 mg/dL decreased 15 
significantly in a prospective study of children with T1DM using PLGM for 6 weeks [9]. In addition, 16 
Battelino T and colleagues carried out a randomized controlled trial of children with T1DM divided 17 
into two groups with or without the use of PLGM for 14 days. They showed that the incidence of 18 
hypoglycemic events with SG values <65 mg/dL was significantly reduced in the PLGM-treated group 19 
during both the daytime and night-time, and there was no increase in hyperglycemic exposure time at 20 
any level (SG value >140 mg/dL, >180 mg/dL and >250 mg /dL) [10]. However, their data 21 
demonstrated that PLGM did not prevent severe hypoglycemia below 50 mg/dL, which is different 22 
from our results. Battelino T and colleagues considered that the participants in their study were 23 
relatively well-managed, the study period was too short, and the overall number of hypoglycemic 24 
events below 50 mg/dL was too small to provide statistically significant results. More recently, the 25 
results of a randomized controlled trial on the presence or absence of 6 months of PLGM use in 154 26 
children and adolescent patients with T1DM were reported. This trial showed that the incidence of 27 
8 
8 
hypoglycemic events with SG values <63 mg/dL decreased significantly in the PLGM group and that 1 
the HbA1c value at 6 months was not significantly different between the two groups: 7.6 ± 1.0% in 2 
the non-PLGM group and 7.8 ± 0.8% in the PLGM group. This result indicated that even when using 3 
PLGM for a long time, glycemic control does not deteriorate [11]. Besides that, Maahs DM et al. 4 
reported that the suspension system reduced nocturnal hypoglycemia (<60 mg/dl) by 12%, median 5 
hypoglycemia area under the curve by 81% and hypoglycemia lasting >2hr by 74%. They also reported 6 
overnight hyperglycemia (>180 mg/dl) was almost same level with or without suspension [12]. 7 
Regarding the hypoglycemia avoidance rate, Choudhary P et al. reported that 82.7% and 84.0% of 8 
predicted hypoglycemia was avoidable in the daytime and the night-time, respectively, by using the 9 
PLGM feature [7], while Zhong et al. reported that the avoidance rate was 73.9% and 77.4%, 10 
respectively [8]. Since our study also showed a rate of hypoglycemia avoidance similar to those in 11 
these reports, PLGM could be expected to suppress hypoglycemic events in Japanese patients with 12 
T1DM. 13 
Next, we investigated the change in the SG value during suspension and after resumption of insulin 14 
infusion. We confirmed that the SG value increased 1 hour after resumption, which is the same as the 15 
findings of previous reports [7, 9, 13-15]. When comparing daytime and night-time, the suspension 16 
time was significantly longer at night, and the SG value at the start, resumption and resumption 1 hour 17 
tended to be lower at night. Biester T et al. reported similar results in which the SG value 1 hour after 18 
resumption was lower at night (174 mg/dL in the daytime vs. 137 mg/dL in the night-time), and the 19 
suspension time during daytime was shorter than during night-time (54 min vs. 68 min) [9]. They 20 
discussed that manual resumption was performed at approximately 46% after insulin suspension, and 21 
as a result, the suspension time was shorter during the daytime, and the rise in SG value 1 hour after 22 
resumption was noted in their article. Although we instructed the participants to avoid manual 23 
resumption and preventive carbohydrate intake after suspension was initiated as much as possible after 24 
the introduction of the PLGM feature, we obtained a similar result as those previously reported. 25 
However, there was no significant difference in SG value after suspension between the daytime and 26 
night-time, and it was considered that higher SG values in the daytime were prevented by instructing 27 
9 
9 
the patients to follow the insulin pump algorithm. The reason the suspension time during the daytime 1 
was longer than during the night-time is that it was necessary to resume insulin infusion manually at 2 
the time of bolus administration at a meal. Moreover, since we could not confirm the manual 3 
resumption rate, there is a possibility that manual resumption was carried out to the same extent as in 4 
the previous report. These results suggested that better glycemic control could be obtained by 5 
following the insulin pump algorithm rather than resuming the insulin infusion manually after PLGM 6 
was initiated. 7 
In addition, we speculated that the time-course changes in the SG value during and after suspension 8 
might be influenced by BMI, TDD, TBD or %TBD, so we compared the SG value and the suspension 9 
time classified with these parameters. Though there were no differences in the SG value and mean 10 
suspension time when classified with BMI, TDD, and TBD, we found the differences of the SG value 11 
at resumption 1 hour classified with %TBD. The reason for this is not clear, but in the low %TBD 12 
group, relatively large amount of bolus insulin might overlay and mask the lack of basal insulin 13 
supplement while basal insulin suspension, resulting in suppression of SG elevation after PLGM. 14 
As shown in Figure 3, there were some cases of hyperglycemia after suspension. Zisser H examined 15 
how much blood glucose would rise after interrupting insulin delivery. He demonstrated the rate of 16 
rise in glucose concentration over 3 h was ~1 mg/dl for each minute insulin infusion was interrupted 17 
[16]. Sherr JL et al. also reported the sensor glucose level rose by 18 ± 58 mg/dl by the end of the 2 18 
h suspension, and by 55 ± 73 mg/dl 4 h after the suspension [17], and Fig. 3a follows their findings. 19 
Fig. 3b shows a rebound hyperglycemia after suspension. In this case, PLGM started just after meal 20 
and the participant ingested carbohydrates without resumption, resulting in rebound hyperglycemia. 21 
Furthermore, this participant may have consumed excess amount of carbohydrate during 22 
hypoglycemia. Collectively, we recognized that early insulin resumption was necessary to prevent 23 
rebound hyperglycemia after carbohydrate intake for hypoglycemia, and we also need to inquire the 24 
patient about amount of carbohydrate during hypoglycemia. Although the initial setting of the lower 25 
limit was 70 mg/dL in this study, depending on the case, the timing of PLGM initiation was early or 26 
10 
10 
the timing of the resumption of insulin infusion was late, and the subsequent increase in the SG value 1 
was marked in some cases. Even though similar severe rebound hyperglycemia after PLGM has been 2 
reported, such risk is believed to be very low [14,15,17,18]. Indeed, there were no cases with marked 3 
hyperglycemia with ketoacidosis in our study. 4 
This study had several limitations. First, this was a small retrospective observational study in a 5 
single facility. Second, the participants were relatively well-managed patients with T1DM (mean 6 
HbA1c 7.0%), so the frequency of hypoglycemia and hyperglycemia may be low. Third, the current 7 
research period is short, only one month before and after PLGM introduction. Because of short 8 
research period, we could not assess sustained effects on metabolic control and HbA1c. Most of the 9 
published studies were limited to short-term evaluation for 2 to 6 weeks [7, 9, 10, 12]. Under longer 10 
observation period for more than 2 months, other factors besides PLGM, such as a change in pump 11 
settings and life-style. Therefore, we set 1 month to assess the real clinical picture of PLGM. In 12 
addition, since we conducted thorough education for the patients before the introduction of 13 
MiniMed®640G system to use the new system safely and effectively, we obtained such good results. 14 
Besides these, we did not consider physical activity in this study. Recently, interesting results were 15 
reported that assessed the optimal setting of the PLGM algorithm for preventing exercise-induced 16 
hypoglycemia in adolescents with T1DM [19]. They concluded that setting a PLGM threshold to 90 17 
mg/dL during the night in adolescents performing frequent physical exercise reduced time of 18 
hypoglycemia; however, a threshold of 70 mg/dL seems to be safe during physical exercise. 19 
It is necessary to further investigate the setting of the lower limit according to each case, time zone, 20 
and the frequency of physical exercise; the timing of manual resumption; and the approach of 21 
preventive carbohydrate intake against hypoglycemia. Finally, although PLGM is a very effective 22 
mechanism, there are some points to be addressed, such as the fact that hypoglycemia cannot be 23 
avoided completely and that there is a possibility of severe hyperglycemia after suspension of insulin 24 
infusion. Therefore, when introducing PLGM, it is necessary to take sufficient time to explain the 25 
features and precautions of this system to patients and to ensure that they use it with full understanding. 26 
11 
11 
1 
Conclusion 2 
In this research, we demonstrated the short-term effects in which the PLGM feature can markedly 3 
suppress hypoglycemia, particularly severe hypoglycemia, without deteriorating glycemic control in 4 
Japanese patients with T1DM. Further examination is necessary to determine the longer-term effects 5 
and to further improve of the hypoglycemia avoidance rate. 6 
7 
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Figure 1. The number of PLGM events and the hypoglycemia avoidance rate 
a: over 24 hours 
b: during the daytime and night-time 
Figure 2. The change in the SG value during suspension and after resumption of insulin infusion 
a: All PLGM data 
b: Classified by event starting time: daytime and night-time. The differences between day and night 
are not significant.  
c: Classified by BMI of patients. The differences between high BMI group and low BMI group are not 
significant. 
d: Classified by %TBD of patients. the SG value at resumption 1 hour was significantly higher in the 
high %TBD group than in the low %TBD group 
SG: sensor glucose, All data are presented as the mean ± standard deviation (SD). 
* Statistically significant, P< 0.05
Figure 3. The cases of hyperglycemia after suspension 
a: A case of hyperglycemia after 2 hours suspension at bedtime 
b: A case of severe hyperglycemia after suspension of insulin infusion because PLGM started just 
after 
a meal 
Arrows show the degree of SG value increase, and squares indicate the time during which PLGM 
was operating. 
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Table 1. Baseline characteristics of the participants 
BMI; body mass index, CSII; continuous subcutaneous insulin infusion, SAP; 
sensor-augmented pump, GA; glycated albumin, TDD; total daily insulin dose; TBD; 
total basal insulin dose, %TBD; the percentage of the total basal insulin dose out of the 
total daily insulin dose. 
Parameter Mean ± standard deviation Range 
N (F) 16 (12) - 
Age (years) 46.1 ± 16.9 17 – 78 
BMI (kg/m2) 22.2 ± 2.6 17.7 – 27.4 
Duration of diabetes (years) 15.8 ± 12.6 2 – 44 
Experience with CSII (years) 5.4 ± 2.7 1.3 – 7.8 
Experience with SAP (years) 2.2 ± 1.0 0.8 – 3.9 
HbA1c (%) 7.0 ± 0.8 5.8 – 8.6 
GA (%) 19.5 ± 4.2 13.0 – 27.5 
TDD (u/day) 40.9 ± 13.0 22.2 – 64.9 
TBD (u/day) 12.2 ± 5.2 5.1 – 22.4 
%TBD (%) 30.9 ± 14.4 17 – 46 
Carbohydrate input value (g/day) 177 ± 64 91 –251 
Table
2 
Table 2. Comparison of glycemic control markers and insulin administration 
status before and after PLGM was introduced 
GA; glycated albumin, TDD; total daily insulin dose, TBD; total basal insulin 
dose, %TBD: the percentage of the total basal insulin dose out of the total daily insulin 
dose. All data are presented as the mean ± standard deviation (SD). 
Baseline PLGM P 
HbA1c (%) 7.0 ± 0.8 7.0 ± 0.9 0.867 
GA (%) 19.5 ± 4.2 20.1 ± 3.5 0.400 
TDD (u/day) 40.9 ± 13.0 38.1 ± 11.4 0.564 
TBD (u/day) 12.2 ± 5.2 11.0 ± 5.2 0.402 
%TBD (%) 30.9 ± 14.4 29.3 ± 13.2 0.616 
Carbohydrate input value (g/day) 177 ± 64 189 ± 73 0.696 
3 
Table 3. Comparison of the CGM data before and after PLGM was introduced 
SG, sensor glucose; AUC, area under the curve. All data are presented as the mean ± 
standard deviation (SD), * P <0.05. 
Baseline PLGM P 
SG value (mg/dl) 155.3 ± 34.0 152.9 ± 44.2 0.669 
Time >180 mg/dL (min/day) 421.3 ± 262.0 440.4 ± 290.1 0.926 
AUC >180 (mg/dL/day) 17.8 ±19.2 16.1 ± 14.0 0.926 
Time <70 mg/dL (min/day) 58.2 ± 49.4 30.1 ± 25.9 0.067 
Time <54 mg/dL (min/day) 15.3 ± 21.7 4.8 ± 6.9 0.019* 
AUC <70 (mg/dL/day) 0.42 ±0.43 0.18 ± 0.18 0.012* 
